Spyre Therapeutics SYRE
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 8th percentile, 5-year average -8.6x
Near the top of its 5-year range · 94th percentile, 5-year average -56.4x
#4977 of 5331 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 100th percentile, 5-year average 2,352.5x
#5145 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 10.91 | – | -56.40 | 94% (pricier than usual) | #4977 of 5331 (1 = cheapest) |
| PE | -37.41 | -24.16 | -8.58 | 8% (cheaper than usual) | – |
| PS | 14,355.81 | – | 2,352.49 | 100% (pricier than usual) | #5145 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on SYRE.
Sign in to join the discussion.